Nogapendekin Alfa Inbakicept

CHEMBL6068330 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A fusion protein combining interleukin-15 (IL-15) with an IL-15 receptor alpha domain, used to stimulate the immune system in combination with BCG for non-muscle-invasive bladder cancer. It enhances natural killer and T cell activity to help the body recognize and eliminate cancer cells.

Area Terapeutik

Bladder Cancer Immunology Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A fusion protein combining interleukin-15 (IL-15) with an IL-15 receptor alpha domain, used to stimulate the immune system in combination with BCG for non-muscle-invasive bladder cancer. It enhances natural killer and T cell activity to help the body recognize and eliminate cancer cells.

Yes, Nogapendekin Alfa Inbakicept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068330. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Nogapendekin Alfa Inbakicept di PillFYI

Data Cepat

Sinonim: 1

Tautan Eksternal

ChEMBL CHEMBL6068330

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.